文献速递脑血管病外科神经重症

他汀类药物治疗与血管内弹簧圈栓塞后颅内动脉瘤复发减少的关联:一项随机临床试验的事后倾向评分匹配分析

The association of statin therapy with reduced intracranial aneurysm recurrence after endovascular coiling: a post hoc propensity score-matched analysis of a randomized clinical trial.
PubMed 文献 · J Neurosurg · 2024-12-20

该研究为对水凝胶血管内动脉瘤治疗试验原发数据的事后分析,纳入577例有他汀使用数据的颅内动脉瘤患者,经倾向评分匹配后比较他汀组与非他汀组弹簧圈栓塞后18-24个月的复发率。他汀组复发率3.8%(6/156) vs 非他汀组10.7%(26/242),p=0.013;未破裂动脉瘤亚组他汀使用显著降低复发(1.6% vs 9.7%,p=0.005),破裂动脉瘤亚组无显著差异(12.5% vs 13.6%,p=0.876)。作者认为他汀使用与复发减少相关,但需进一步前瞻性研究验证。

要点

  • 倾向评分匹配后他汀组动脉瘤复发率3.8%(6/156) vs 非他汀组10.7%(26/242),p=0.013。
  • 未破裂动脉瘤亚组他汀使用显著降低复发(1.6% vs 9.7%,p=0.005)。
  • 破裂动脉瘤亚组他汀使用与复发无显著差异(12.5% vs 13.6%,p=0.876)。

核心结论

  • 他汀使用与血管内弹簧圈栓塞的颅内动脉瘤患者动脉瘤复发率降低相关,随访期间再治疗率亦降低。
  • 他汀是相对低风险的治疗,可能是减少颅内动脉瘤再通的有效疗法,但需进一步前瞻性研究验证这些发现。

研究设计与样本

  • 对水凝胶血管内动脉瘤治疗试验入组患者原发数据的事后分析,聚焦他汀使用对3-14 mm颅内动脉瘤血管内弹簧圈栓塞后复发率的影响。
  • 共577例有他汀使用数据的患者纳入分析,其中178例(30.8%)使用他汀,399例(69.2%)未使用。
  • 基于患者和动脉瘤特征进行倾向评分匹配以减轻选择偏倚,匹配后他汀组156例(39.2%),非他汀组242例(60.8%)。

主要发现

  • 主要结局为采用Raymond-Roy闭塞分类评估18-24个月内的动脉瘤复发,他汀组复发率3.8%(6/156) vs 非他汀组10.7%(26/242),p=0.013。
  • 亚组分析中,他汀使用显著降低未破裂动脉瘤患者的复发率(1.6% vs 9.7%,p=0.005)。
  • 破裂动脉瘤患者中他汀使用与复发无显著差异(12.5% vs 13.6%,p=0.876)。
  • 次要结局包括主要和次要复发率及再治疗率,他汀使用与随访期间再治疗率降低相关。

临床怎么用

  • 作者认为他汀是相对低风险的治疗,可能是减少颅内动脉瘤再通的有效疗法。
  • 作者指出需进一步前瞻性研究验证这些发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endovascular intracranial aneurysm (IA) management has significantly evolved over the last 2 decades. Despite these advancements, the aneurysm recanalization rate after coil embolization remains a concern. Statins have been found to affect vascular repair and remodeling; therefore, the authors hypothesized that patients receiving statin therapy at the time of coil embolization would have lower aneurysm recurrence and retreatment rates compared with patients not receiving statin therapy. METHODS: A post hoc analysis was conducted of the primary data from patients enrolled in the Hydrogel Endovascular Aneurysm Treatment Trial focusing on the impact of statin use on the recurrence rates of 3- to 14-mm IAs after endovascular coiling. The primary outcome measured included aneurysm recurrence over 18-24 months using the Raymond-Roy Occlusion Classification. Secondary outcomes included major and minor recurrence rates and retreatment rates. Propensity score matching based on patient and aneurysm characteristics was performed to mitigate selection bias. RESULTS: A total of 577 patients with data on statin use were eligible for this analysis. Of these, 178 (30.8%) patients were using statins and 399 (69.2%) were not. After propensity score matching, 156 (39.2%) patients were included in the statin group and 242 (60.8%) in the nonstatin group. The recurrence rate was 3.8% (6/156) in the statin group and 10.7% (26/242) in the nonstatin group (p = 0.013). In a subgroup analysis, statin use significantly reduced recurrence in patients with unruptured aneurysms (1.6% vs 9.7%, p = 0.005), but not in those with ruptured aneurysms (12.5% vs 13.6%, p = 0.876). CONCLUSIONS: Statin use was associated with a reduced rate of aneurysm recurrence in patients who underwent endovascular coiling for IAs with a decreased rate of retreatment during the follow-up period. Statins are a relatively low-risk treatment and may be an effective therapy to reduce recanalization of IAs, although further prospective studies are warranted to validate these findings.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Patra DP, Abi-Aad KR, Turcotte EL, et al. The association of statin therapy with reduced intracranial aneurysm recurrence after endovascular coiling: a post hoc propensity score-matched analysis of a randomized clinical trial. J Neurosurg. 2024. PMID: 39705700. doi:10.3171/2024.7.JNS24781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。